The duchenne muscular dystrophy drugs market size was valued at USD 4.00 billion in 2024 and is expected to reach USD 13.71 billion by 2032, growing at a CAGR of 16.67% over the forecast period of 2025-2032.
The global duchenne muscular dystrophy drugs market is expected to grow at a rapid pace, mainly due to the huge progress in gene therapy, which targets the primary root of the genetic cause instead of only treating the symptoms. FDA approval of paradigm-shifting treatments, including Sarepta’s ELEVIDYS, has changed the narrative over symptom management to curative potential, escalating market demand, and investment. Gene therapies that provide functioning dystrophin genes also appear to be a runway to muscle strength recovery, given strong R&D pipelines. Whilst safety and cost issues remain, continued advances in vector design and manufacturing are generating improvements in outcomes and access, underpinning commercial opportunities and patient adoption in the U.S., Europe, and beyond.
For instance, on 28 February 2024, Sarepta reported USD 135 million in Q4 2023 ELEVIDYS sales, projecting over USD 500 million in 2024 due to expanded commercial uptake.Top of Form
The U.S. Duchenne Muscular Dystrophy Drugs Market was valued at USD 1.54 billion in 2024 and is expected to reach USD 5.21 billion by 2032, growing at a CAGR of 16.53% over 2025-2032.
The U.S. dominates the Duchenne muscular dystrophy drugs market due to accelerated FDA approvals, aid from the government for rare disease treatment, and the urgent need for innovative drugs in the paediatric sector. Policies are tending to favour fast-track access with surrogate endpoints, including micro-dystrophin expression, allowing an early uptake of gene therapies, including Sarepta’s Elevidys. Moreover, the U.S. health care system often funnels expensive treatments through strong reimbursement channels. These factors lead the U.S. having the largest duchenne muscular dystrophy drugs market share globally and are expected to grow at a rapid pace and innovate.
For instance, in June 2024, the FDA expanded Elevidys' approval to non-ambulatory DMD patients aged 4+, increasing the eligible U.S. patient pool by over 40%, boosting market growth.
Drivers:
Rising Incidence and Prevalence, Driving the Duchenne Muscular Dystrophy Drugs Market Growth
The rising incidence of duchenne muscular dystrophy in developing countries will remain the key driver of the Duchenne muscular dystrophy market's growing patient pool. This is the impetus for pharmaceutical research and development in gene and exon-skipping therapies, earlier diagnosis, and greater therapy eligibility. Higher prevalence in North America and Asia Pacific, and a conducive healthcare system and funding aid the adoption and progression of the expected Duchenne muscular dystrophy drugs market through 2030.
For instance, in April 2024, the U.S. CDC and Japan expanded newborn screening for DMD, targeting to boost early diagnoses by 25%–30% over the next five years.
Restraints:
Diagnostic Delays in Duchenne Muscular Dystrophy, Restraining the Duchenne Muscular Dystrophy Drugs Market Growth
Diagnostic delays in duchenne muscular dystrophy result in anxiety, heartache, and frustration for the families, which further underlines the need for early intervention. These mental strains and lost treatment windows underscore the urgent need for faster diagnosis and mental health assistance. As prevalence increases, it promotes early screening, early diagnosis, and demand for effective treatments, which also accelerates the duchenne muscular dystrophy drugs market growth by inducing a global increase in the size and growth of the market.
For instance, in January 2025, A survey showed 41% of DMD parents experience moderate to severe anxiety, with late diagnoses doubling emotional burnout, highlighting the urgent need for faster diagnosis and support.
By Treatment
Molecular-Based Therapies were the dominant segment in the Duchenne muscular dystrophy drugs market analysis, with a market share of 43.86% share in 2024, owing to their specific influence on the genetic basis of the disease, with enhanced potency compared with standard therapies. This section holds the majority of the Duchenne muscular dystrophy drugs market share, driven by improved FDA-approved tests, an increase in R&D spending, and a surge in unmet clinical needs.
Steroid-based therapies are emerging as the fastest-growing segment in the duchenne muscular dystrophy drugs market trend, with the highest CAGR of 17.23% over the forecast period, as they are known to slow down muscle degeneration and restore mobility. These treatments are widely available and are being increasingly recommended at an early stage of the condition in support of disease management. Their low cost and proven clinical efficacy are the major factors that boost the Duchenne muscular dystrophy drugs market growth, particularly in developing regions with economic constraints.
By Distribution Channel
In 2024, the Hospital Pharmacies segment controlled the global Duchenne muscular dystrophy drugs market share, owing to their vital role in the execution of complex treatments, including gene therapy, and controlling very expensive specialty medications. Their potential for integration with diagnostic and specialist care allows for precisely-timed drug delivery. It is estimated that this segment will hold the maximum share of the duchenne muscular dystrophy drugs industry, owing to centralized treatment guidelines and improved patient access in hospitals.
The Online Pharmacies are the fastest-growing segment in the Duchenne muscular dystrophy drugs industry, fuelled by growing digital adoption, home delivery convenience, and better availability in far-flung regions. Demand is further raised by the rising levels of awareness, by patient assistance programs, and by the growing integration of telemedicine. In remote areas and technology-enabled spaces, the new model improves access to treatment and makes a key contribution to the Duchenne muscular dystrophy drugs market growth.
In 2024, the North American region dominated the duchenne muscular dystrophy drugs industry and accounted for 45.60% of the overall revenue share, owing to its well-established system of healthcare, early diagnosis initiatives, and access to sophisticated treatments. The numbers support rapid adoption of new therapies, with major pharmaceutical companies on the ground, robust regulatory environments courtesy of the FDA’s accelerated approval process, and high healthcare spending. Furthermore, higher patient health awareness levels, insurance coverage have promoted the therapy adoption rate, and thereby the region in North America is dominating the Light-Therapy market in terms of the market value and innovation. With ongoing clinical trials, government initiatives, and early intervention strategies, the duchenne muscular dystrophy treatment space is witnessing steady growth throughout the region.
Europe accounts for the second-largest duchenne muscular dystrophy drugs market share, owing to good healthcare infrastructure, Government support, including EMA, and early adoption of treatments, including Translarna and Viltepso. Diagnosis and access are improved by government-supported rare disease programs and expanded newborn screening. Moreover, the rising number of clinical trials and partnerships with biotech companies are viewed as another factor for the increased treatment options that are available, further adding to the sizeable presence of Europe within the Global Duchenne muscular dystrophy drugs industry landscape.
The Asia Pacific region is projected to grow with the fastest CAGR of 17.39% over the forecast period, with growing awareness of disorders, growth in healthcare spending, and greater availability of modern therapies. Nations and systems, including Japan, China, and South Korea, are making significant efforts to fund rare disease research and diagnostics, resulting in earlier diagnosis and initiation of treatment. Government developments are also enhancing affordability and access. Government efforts to incorporate DMD in the national health coverage and rare disease programs are facilitating the expansion of both affordability and access. Furthermore, local pharmaceutical companies were making their way into the market through partnerships and clinical trials, speeding the drug development process. The increasing population, a developed regulatory framework, and an increase in the online pharmacy platforms are also having a positive impact on therapy adoption. All these factors are fueling robust duchenne muscular dystrophy drugs market growth in Asia Pacific
The Middle East & Africa are a relatively smaller but emerging region in the duchenne muscular dystrophy drugs market, on the back of increasing healthcare penetration and increasing rare disease awareness. Another driving factor of the growth in the Middle East is the increased importance of genetic counselling and consanguinity screening programs, especially in the Gulf states, where inherited diseases are common. Government initiatives to establish rare disease registries also contribute to early diagnosis and the availability of future treatment.
The Latin American market is developing in the duchenne muscular dystrophy drugs industry, as the diagnosis rate is expanding, healthcare infrastructure is improving, and healthcare professionals are becoming more aware. Countries including Brazil and Mexico are putting in place rare disease policies and broadening access to life-saving treatments. Nevertheless, obstacles must be overcome by inadequate reimbursement models and high cost of treatment, which causes global non-implementation. The situation is slowly being changed by clinical trials and advocacy.
Duchenne muscular dystrophy drug companies include Sarepta Therapeutics, PTC Therapeutics, Pfizer Inc., NS Pharma, Wave Life Sciences, Santhera Pharmaceuticals, ReveraGen BioPharma, Dyne Therapeutics, Entrada Therapeutics, Genethon, and other players.
In June 2024, Sarepta received expanded FDA approval for ELEVIDYS, a gene therapy, to treat ambulatory children with DMD aged 4 to 5, regardless of mutation type.
In January 2024, Pfizer shared top-line data over the global CIFFREO Phase 3 trial for fordadistrogene movaparvovec (gene therapy). Results showed no statistical significance in primary endpoints.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 4.00 billion |
| Market Size by 2032 | USD 13.71 billion |
| CAGR | CAGR of 16.67% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Treatment (Molecular-Based Therapies, Steroid-Based Therapies, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Others) •By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)" |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Sarepta Therapeutics, PTC Therapeutics, Pfizer Inc., NS Pharma, Wave Life Sciences, Santhera Pharmaceuticals, ReveraGen BioPharma, Dyne Therapeutics, Entrada Therapeutics, Genethon, and other players |
Ans. The current market size for the Duchenne Muscular Dystrophy Drugs Market is USD 4.66 billion.
Ans: Rising Incidence and Prevalence, Driving the Duchenne Muscular Dystrophy Drugs Market Growth
Ans. North America regions are leading the growth in the Duchenne Muscular Dystrophy Drugs Market
Ans: The Duchenne Muscular Dystrophy Drugs Market is growing at a CAGR of 16.67% over 2025 to 2032.
Ans: Sarepta Therapeutics, PTC Therapeutics, Pfizer Inc., NS Pharma, Wave Life Sciences, and Santhera Pharmaceuticals are the leading players in the global Duchenne Muscular Dystrophy Drugs Market.
Table of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
Incidence & Prevalence (2023)
Prescription Trends (2023)
Drug Volume (Production & Usage)
Healthcare Spending (2023), by Region & Source
Regulatory and Market Trends (2024 Outlook)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Duchenne Muscular Dystrophy Drugs Market Segmentation By Treatment
7.1 Chapter Overview
7.2 Molecular-Based Therapies
7.2.1 Molecular-Based Therapies Trend Analysis (2021-2032)
7.2.2 Molecular-Based Therapies Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Steroid-Based Therapies
7.3.1Steroid-Based Therapies Trends Analysis (2021-2032)
7.3.2 Steroid-Based TherapiesMarket Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Non-steroidal Anti-Inflammatory Drugs
7.4.1Non-steroidal Anti-Inflammatory Drugs Trends Analysis (2021-2032)
7.4.2 Non-steroidal Anti-Inflammatory Drugs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Others
7.5.1Others Trends Analysis (2021-2032)
7.5.2 OthersMarket Size Estimates and Forecasts to 2032 (USD Billion)
8. Duchenne Muscular Dystrophy Drugs Market Segmentation By Distribution Channel
8.1 Chapter Overview
8.2 Hospital Pharmacies
8.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
8.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Retail Pharmacies
8.3.1 Retail Pharmacies Market Trends Analysis (2021-2032)
8.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Online Pharmacies
8.4.1 Online Pharmacies Market Trends Analysis (2021-2032)
8.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.2.4 North America Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.2.5.2 USA Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.2.6.2 Canada Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.2.7.2 Mexico Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.4 Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.5.2 Germany Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.6.2 France Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.7.2 UK Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.8.2 Italy Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.9.2 Spain Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.10.2 Poland Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.11.2 Turkey Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.4.4 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.4.5.2 China Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.4.5.2 India Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.4.5.2 Japan Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.4.6.2 South Korea Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.4.7.2 Singapore Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
8.4.8.2 Australia Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.5.5.2 UAE Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.5.7.2 Qatar Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.5.8.2 South Africa Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.6.4 Latin America Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.6.5.2 Brazil Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.6.6.2 Argentina Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Treatment (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10. Company Profiles
10.1 Sarepta Therapeutics
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 PTC Therapeutics
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Pfizer Inc.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 NS Pharma
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Wave Life Sciences
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Santhera Pharmaceuticals
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 ReveraGen BioPharma
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Dyne Therapeutics
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 Entrada Therapeutics
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 Genethon
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Treatment
Molecular-Based Therapies
Steroid-Based Therapies
Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players